Polyrizon Ltd. Ordinary Shares PLRZ 深 沪
等待开盘 08-27 09:30:00 美东时间
1.05
+0.030
+2.94%
华盛通- 最 高1.05
- 今 开1.02
- 成交量 45.08万股
- 最 低 1.00
- 昨 收 1.02
- 总市值 559.47万
- 52周最高 1200.00
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.55
- 委 比 -96.78%
- 总股本 532.83万
- 历史最高 1200.00
- 量 比 1.49
- 振 幅 4.90%
- 历史最低 0.80
- 每 手 1
- 风险率 167.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Polyrizon shares are trading higher after the company announced it regained Nasdaq compliance.
Polyrizon shares are trading higher after the company announced it regained Nas...
08-14 23:53
Polyrizon Regains Compliance With Nasdaq Listing Requirements
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the Hearings Advisor
08-14 20:44
Polyrizon Regains Compliance with Nasdaq Listing Requirements
Polyrizon Ltd. (Nasdaq: PLRZ) announced it has regained compliance with Nasdaq listing requirements, allowing it to continue trading on the Nasdaq Capital Market under the ticker "PLRZ." The company met the minimum bid price requirement and satisfied conditions set by the Nasdaq Hearings Panel. Polyrizon specializes in developing intranasal hydrogel products, including its Capture and ContainTM (C&C) technology, designed to form a protective barr...
08-14 12:14
Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket
Shares of Vicor Corporation (NASDAQ:VICR) rose sharply in pre-market trading after posting second-quarter results.
07-23 17:00
Polyrizon Achieves Breakthrough in Allergy Blocker Study
An update from Polyrizon Ltd. ( ($PLRZ) ) is now available. On July 22, 2025, P...
07-22 21:27
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon Ltd. announced positive preclinical results for its PL-14 Allergy Blocker, part of its Capture & Contain platform. The study, conducted with the University of Parma, showed over 60% deposition of PL-14 in the nasal vestibule, critical for blocking allergen contact and preventing allergic rhinitis. CEO Tomer Izraeli highlighted the significance of these results for forming a protective barrier at the allergen entry point. The global ...
07-22 12:32
Polyrizon shares are trading higher after the company announced it has retained its Nasdaq listing following a hearing panel.
Polyrizon shares are trading higher after the company announced it has retained...
07-15 20:40
Polyrizon Retains Nasdaq Listing Following Hearings Panel
Polyrizon Ltd. received a Nasdaq notification granting its request to continue listing on the Nasdaq Capital Market. The decision, following a hearing on June 26, 2025, allows the company to remain listed pending its compliance with the Minimum Bid Price Rule by October 17, 2025. Polyrizon had previously issued 5,962,073 ordinary shares through a private placement involving warrants. The company committed to avoiding overly complex financing inst...
07-15 11:55
Polyrizon shares are trading higher after the company reported preclinical results showing its Trap & Target formulation achieved targeted deposition in the upper nasal cavity.
Polyrizon shares are trading higher after the company reported preclinical resu...
06-12 19:44
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
Polyrizon Ltd. has announced promising preclinical results from a study evaluating its hydrogel-based Trap & Target (T&T) platform for CNS drug delivery. The study, conducted with the University of Parma, showed that the hydrogel achieves targeted deposition in the upper nasal regions, critical for nose-to-brain transport. This could significantly benefit treatments for conditions like opioid overdose and epileptic seizures. Polyrizon plans to va...
06-12 11:32
